pensyarah universiti
institut biologi molekul perubatan ukm (umbi)
m.aimanmohtar@ppukm.ukm.edu.my
Biografi/ Biography :
M. Aiman Mohtar is a Research Fellow at the UKM Medical Molecular Biology Institute (UMBI), The National University of Malaysia. He previously earned his BSc. (Biotechnology) with highest honours from Rochester Institute of Technology, New York and MSc. (Molecular Biology) from University of Pennsylvania, Philadelphia. He completed his PhD in Molecular and Clinical Medicine at Institute of Genetics and Molecular Medicine, University of Edinburgh. His PhD thesis focuses on identification of protein-protein interaction network of an oncogenic ER-resident protein. He has been trained as molecular biologist for more than a decade and has involved in research utilizing cutting- edge laboratory techniques such as CRISPR-Cas9 genome editing tools, fluorescence microscopy, phage display and quantitative proteomics. Aiman’s current research focus is studying protein-protein interaction and tumour cell secretory addiction in AGR2 signalling axis using multi-omics approach and developing therapeutic tools targeting pro-oncogenic molecules. To date, he has secured several UKM, national and international grants.
mohamad aimanuddin bin mohtar;saiful effendi bin syafruddin;low teck yew. (2024). elucidating the secretome of crispr/cas9 mediated agr2-knockout breast cancer cells. - . .
m. aiman mohtar, siti nur hasanah mohd yusuf, and saiful effendi syafruddin. (2024). cholesterol accumulation in ccrcc: the role of ccrcc-initiating vhl-hifa pathway. - ebiomedicine. 1-2.
nurul nadia mohamad zamberi, asmaa y abuhamad, teck yew low, m aiman mohtar, saiful effendi syafruddin. (2024). dcas9 tells tales: probing gene function and transcription regulation in cancer. - the crispr journal. 73-87.
syazalina zahari , saiful effendi syafruddin , m. aiman mohtar. (2023). cancer cell secretome in driving breast cancer progression. - scholarly community encyclopedia. 1-8.
yuh cai chia, sundharavalli ramayah , nurul nadia mohamad zamberi, mohamad aimanuddin mohtar , saiful effendi syafruddin. (2023). crispr/cas9: teknik penyuntingan dan modifikasi gen. - . 1.
m. aiman mohtar, siti nur hasanah mohd yusuf, and saiful effendi syafruddin. (2024). cholesterol accumulation in ccrcc: the role of ccrcc-initiating vhl-hifa pathway. - ebiomedicine. 1-2.
nurul nadia mohamad zamberi, asmaa y abuhamad, teck yew low, m aiman mohtar, saiful effendi syafruddin. (2024). dcas9 tells tales: probing gene function and transcription regulation in cancer. - the crispr journal. 73-87.
syazalina zahari, saiful effendi syafruddin and m. aiman mohtar. (2023). impact of the cancer cell secretome in driving breast cancer progression. - cancers. 1-17.
m. aiman mohtar, syazalina zahari, nisa syakila a. rahman, saiful effendi, muhammad-redha abdullah-zawawi, teck yew low, ted hupp. (2023). rna-seq analysis of crispr-cas9 targeted agr2 of breast cancer cells reveals potential modulators of its expression and secretion. - esmo open. 6.
asmaa y. abuhamad, nurul nadia mohamad zamberi, sakari vanharanta, siti nur hasanah mohd yusuf, m. aiman mohtar, saiful effendi syafruddin. (2023). cancer cell-derived pdgfb stimulates mtorc1 activation in renal carcinoma. - international journal of molecular sciences. 1-14.
saiful effendi syafruddin, wan fahmi wan mohamad nazarie, nurshahirah ashikin moidu, bee hong soon, m. aiman mohtar. (2021). integration of rna-seq and proteomics data identifies glioblastoma multiforme surfaceome signature. - bmc cancer. 1-13.
m. aiman mohtar, siti nur hasanah mohd yusuf, and saiful effendi syafruddin. (2024). cholesterol accumulation in ccrcc: the role of ccrcc-initiating vhl-hifa pathway. - ebiomedicine. 1-2.
nurul nadia mohamad zamberi, asmaa y abuhamad, teck yew low, m aiman mohtar, saiful effendi syafruddin. (2024). dcas9 tells tales: probing gene function and transcription regulation in cancer. - the crispr journal. 73-87.
m. aiman mohtar, syazalina zahari, nisa syakila a. rahman, saiful effendi, muhammad-redha abdullah-zawawi, teck yew low, ted hupp. (2023). rna-seq analysis of crispr-cas9 targeted agr2 of breast cancer cells reveals potential modulators of its expression and secretion. - esmo open. 6.
asmaa y. abuhamad, nurul nadia mohamad zamberi, sakari vanharanta, siti nur hasanah mohd yusuf, m. aiman mohtar, saiful effendi syafruddin. (2023). cancer cell-derived pdgfb stimulates mtorc1 activation in renal carcinoma. - international journal of molecular sciences. 1-14.
syazalina zahari, saiful effendi syafruddin and m. aiman mohtar. (2023). impact of the cancer cell secretome in driving breast cancer progression. - cancers. 1-17.
saiful effendi syafruddin, mohamad aimanuddin mohtar, tan shing cheng, nadiah abu, nor aidatulakma abdullah@muda, nurul syakima ab mutalib, chin siok fong, neoh hui min, rahman jamal, nor azian abdul murad. (2019). malaysian higher institution centres of excellence (hicoe) official compendium. - . 244.
mohamad aimanuddin bin mohtar;saiful effendi bin syafruddin;low teck yew. (2024). elucidating the secretome of crispr/cas9 mediated agr2-knockout breast cancer cells. - . .
saiful effendi bin syafruddin;muhiddin bin ishak;mohamad aimanuddin bin mohtar;low teck yew. (2023). functional validation of crispr-cas9 genetic screening hit hsf4 in supporting clear cell renal cell carcinoma pathogenesis. - . .
ahmad rifqi bin md zain;tengku hasnan bin tengku abdul aziz;saiful effendi bin syafruddin;mohamad aimanuddin bin mohtar. (2023). optical sensor technique based on high quality factor suspended 1d photonic crystal (phc) structures for creatinine detection using non-invasive approach.. - . .
syazalina zahari , saiful effendi syafruddin , m. aiman mohtar. (2023). cancer cell secretome in driving breast cancer progression. - scholarly community encyclopedia. 1-8.
saiful effendi syafruddin, asmaa y. abuhamad, nurul nadia mohamad zamberi, siti nur hasanah mohd yusuf, m. aiman mohtar. (2023). cancer cell-derived pdgfb stimulates mtorc1 activation in renal carcinoma. - 6th international conference on molecular biology and biotechnology (icmbb). 1-15.
| Geran / Grant | Kolaborator / Collaborator | Status |
|---|---|---|
| INVESTIGATING ENGINEERED NANOVESICLE CAPTURING AGENT AGAINST PRO-ANGIOGENIC VEGFA IN RENAL CARCINOMA | genscript biotech (singapore) private limited | 44.5% (2025-03-03 sehingga 2026-03-02) |
| ELUCIDATING THE CROSSTALK BETWEEN HIF2α-VEGFA AND KLF6-PDGFβ AXES IN DRIVING RENAL CARCINOMA HYPERVASCULARIZATION | nanoarms sdn. bhd. | 74.7% (2023-10-01 sehingga 2026-03-31) |
| ELUCIDATING THE CROSSTALK BETWEEN HIF2α-VEGFA AND KLF6-PDGFβ AXES IN DRIVING RENAL CARCINOMA HYPERVASCULARIZATION | genomax technologies sdn bhd | 74.7% (2023-10-01 sehingga 2026-03-31) |